**Title**

A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors

**Authors**

David J Young, Bao Nguyen, Li Li, Tomoyasu Higashimoto, Jun O Liu, Mark J Levis, and Donald Small

**Supplemental Table 1: Validation cohort patient characteristics.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Patient | Age | Sex | WBC  (x 103 / µL) | Notes |
| 1 | 69 y | Male | 26.9 | Spontaneous tumor lysis syndrome |
| 3 | 53 y | Female | 57.2 | 70% circulating blasts |
| 4 | 55 y | Female | 55.1 | FLT3/ITD, newly relapsed |
| 5 | 31 y | Female | 13.2 |  |
| 6 | 33 y | Female | 0.6 | Peritonsillar abscess at diagnosis |
| 7 | 66 y | Male | 1.5 | Prior non-small cell lung cancer, likely treatment-related AML |
| 8 | 81 y | Male | 2.0 | EZH2 and STAT5B/N562K mutations |
| 9 | 33 y | Female | 70.7 | 88% circulating blasts |
| 10 | 57 y | Female | N/A | History of polycythemia vera with JAK2/V617F mutation |
| 11 | 70 y | Female | 53.9 | History of ovarian cancer, initially presented with WBC >300 |
| Plasma sample from patient 2 found to be toxic to MOLM-14 cells, and assay could not be performed. | | | | |